Click Preview case to review the first page of this case
David Pyott: The Battle for Allergan (B)
By Randall Peterson, Lisa Duke
This case series charts the evolution of the hostile battle for Allergan and its ultimate sale to a white knight, Actavis. David Pyott had been the CEO of Allergan since January 1998; only the third CEO in the company’s 60-year-plus history. Allergan was primarily known for Botox, the aesthetic anti-wrinkle product, but the company, which had started out in eye care, had developed Botox into a US$2 billion multipurpose drug. By 2014 the company, which enjoyed double-digit growth, had over 11,000 employees, sold its products in 100 countries and had 40 direct-selling subsidiaries. The business mix included eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics. R&D was the backbone of the company and it had strong cash reserves. In April 2014 it came as a shock to Pyott and the Allergan board to learn that that pharma company Valeant, in partnership with Pershing Square Capital Management, had announced its intention to make a hostile takeover of Allergan. The ensuing battle was hostile, attracting media interest, hostile and supportive stories in the papers, and ‘games’ to force Allergan into negotiating a sale. Tricks included hacking emails in an attempt to find out information on the fight team’s strategy and moves. Pyott and the board had managed to drive up the share price over several months in their attempt to keep Allergan independent. In November 2014, a Californian judge accepted Valeant/Pershing Square’s demand that shareholders should be allowed to vote on its bid. Case A follows the battle from the initial announcement to the court judgement. Case B then illustrates what happened next. Pyott and the ‘fight’ team realised that they were not able to keep Allergan independent and looked for a white knight to make a higher bid for the company. They successfully identified and negotiated with Actavis, a fellow pharma company. The sale was announced later in November. While Allergan no longer remained an independent company, a short time later Actavis announced it was changing the name of the company to Allergan, rather than simply absorbing Allergan into the Actavis name.
- Leadership matters more in a crisis than in ‘business-as-usual’ situations.
- Values are essential for managing in difficult times. They provide direction, help managers make sense of fast-moving situations and suggest answers to very difficult situations.
- Values do have a downside – they can create moral outrage when those values are questioned. Moral outrage can blind people to alternative perspectives; in this case, accusations of narcissism, ignoring shareholder value and engaging in self-serving behaviour in refusing the Valeant offers.
- Motivating followers through a crisis requires planning and attention.
- Sometimes the most dangerous part of crisis management is not the crisis but the lack of attention to the day-to-day realities and demands of the business. In this case, Pyott successfully managed these two separate demands by creating two senior management teams, one for the crisis and one to manage the business."
|Publication Date:||September 2018|
|LBS Case Code:||CS-16-001b|
|Subjects:||Crisis management, Leadership, Mergers & Acquisitions|